Skip to main content
. 2015 Feb 18;125(15):2336–2343. doi: 10.1182/blood-2014-08-595934

Figure 7.

Figure 7

Inhibition of chemokines and cytokines in subjects with CLL after treatment with entospletinib. Serum levels of BCR-mediated chemokines/cytokines, including CCL3/MIP-1α, CCL4/MIP-1β, CCL22/MDC, and tumor necrosis factor α, were measured on day 1 before entospletinib treatment and on days 8 and 29 by Luminex (Life Technologies/Thermo Fisher Scientific, Waltham, MA) immunoassays (n = 40). Entospletinib reduced mean plasma levels of all measured chemokines/cytokines over time (nominal P < .0001).